[Competitive new generation myorelaxants in pediatric neuroanesthesia].
Two groups of 50 children were included in a study to examine the use of atracurium and vecuronium. In both groups, newborns and infants showed a shorter onset time and a longer clinical duration of the first dose of the neuromuscular blocking drug. The duration of subsequent doses in the various age groups was not significantly different. Atracurium and vecuronium both have a short recovery index, good cardiovascular stability and do not interfere with ICP. The Authors emphasise the importance of monitoring the use of neuromuscular blocking drugs.
Gifuni
D
D
Sezione di Neuroanestesia, USL n. 40, Ospedale Santobono, Napoli.
Frangiosa
A
A
Geri
A
A
Graziano
D V
DV
D001279:Atracurium / Q000494:pharmacology*; D001921:Brain / Q000601:surgery; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D014673:Vecuronium Bromide / Q000494:pharmacology*
D001279:Atracurium; D014673:Vecuronium Bromide
I miorilassanti competitivi di nuova generazione in neuroanestesia pediatrica.